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Abstract
A p21-activated kinase 6 (PAK6) was previously identified to be an androgen receptor (AR) interacting protein
through a yeast two-hybrid screening. We used hormone responsive prostate cancer LAPC4 and LNCap cell lines as
models to study the signaling events associated with androgen stimulation and PAK6. An androgen-stimulated PAK6
kinase activation was observed in LAPC4 cells expressing endogenous PAK6 and in LNCap cells ectopically
expressing a wild type PAK6. This activation was likely mediated through a direct interaction between AR and PAK6
since siRNA knock-down of AR in LAPC4 cells downregulated androgen-stimulated PAK6 activation. In addition,
LNCap cells expressing a non-AR-interacting PAK6 mutant exhibited dampened androgen-stimulated kinase
activation. As a consequence of androgen-stimulated activation, PAK6 was phosphorylated at multiple serine/
threonine residues including the AR-interacting domain of PAK6. Furthermore, androgen-stimulation promoted
prostate cancer cell motility and invasion were demonstrated in LNCap cells ectopically expressing PAK6-WT. In
contrast, LNCap expressing non-AR-interacting mutant PAK6 did not respond to androgen stimulation with increased
cell motility and invasion. Our results demonstrate that androgen-stimulated PAK6 activation is mediated through a
direct interaction between AR and PAK6 and PAK6 activation promotes prostate cancer cells motility and invasion.
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Introduction
The p21-activated kinases (PAKs) are a family of serine/
threonine kinases sharing a conserved N-terminal Cdc42/Rac-
interacting-binding domain (CRIB) and a C-terminal kinase
catalytic domain [1,2]. Six members of this family, PAK 1-6,
have been identified in mammalian cells thus far. Based on
their sequence and structural similarities, PAKs have been
categorized into Group 1 (PAK 1, 2 and 3) and Group 2 (PAK
4, 5 and 6) [3]. Group 1 PAK has a functional auto-inhibitory
domain (AID) that flanks CRIB domain C-terminus to negatively
regulate catalytic activity of the kinase. At resting stage, Group
1 PAKs exist as autoinhibited-dimers in which the catalytic
activity is blocked by a direct interaction between the kinase
domain and AID. Upon binding of p21 GTPase, GTP-Cdc42 or
-Rac, to the CRIB domain, the AID blockade is released
resulting in phosphorylation in the activation loop and
subsequent kinase activation. The existence of a functional AID
for Group 2 PAKs, PAK4 and PAK6, was demonstrated only
recently [4,5]. Although the AIDs are somewhat conserved from
both groups, it was demonstrated that the activation
mechanism of Group 2 PAKs involves mainly the
conformational change-induced ‘unlocking’ of the catalytic
domain without an Activation-loop phosphorylation step [4,5].
Various cellular events, such as reorganizing cytoskeleton,
modulating cell morphology, and promoting cell motility and cell
survival, have been previously determined as downstream
targets of Group 1 PAK, whereas much of the regulation and
biological role of Group 2 PAK remains undefined. Many lines
of evidence do suggest functional overlaps between these two
groups. For example, PAK4 has been demonstrated to mediate
cytoskeleton reorganization and filapodia formation in response
to HGF stimulation [6,7]. Both PAK1 and PAK5 have been
shown to regulate apoptosis by blocking proapoptotic BAD
mitochondria translocation via phosphorylation of Serine 112
[8-10]. On the other hand, unlike Group 1 PAKs, Group 2 PAKs
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failed to rescue the Ste20 kinase mutant in a S. cerevisiae
functional complementation test, suggesting divergent
downstream targets between these Groups [8]. The division
can be further illustrated by the less than ubiquitous tissue
distribution of PAK5 and PAK6 as compared to the Group 1
PAKs [11]. As demonstrated by Northern blot analysis, PAK6
expression is highest in brain, testis, and prostate [1]. In
prostate cancer cell lines, PAK6 expression is detected at
higher levels in PC3, LAPC4, DU145 cells but not in LNCap
cells [2]. While PAK6 does not appear to function directly as a
cofactor in modulating androgen receptor (AR) transcriptional
activity, the androgen-dependent interaction between PAK6
and AR suggest a potential crosstalk between these two
pathways.
In the present study, we demonstrate that androgen
stimulation acts as an extracellular signal that activates PAK6
in an AR-dependent manner in prostate cancer LAPC4 and
LNCap cells. The androgen-stimulated activation of PAK6 is
accompanied by increased prostate cancer cell motility and
invasion. Our results indicate that the interaction between
PAK6 and AR is responsible, at least in part, for the activation
of PAK6 in prostate cancer cells in response to androgen
stimulation since knock-down of AR expression by AR-specific
siRNA in LAPC4 cells downregulates androgen-stimulated
PAK6 activation. LNCap cells expressing PAK6-WT, but not
non-AR-interacting PAK6 mutant, respond to androgen
stimulation with increased cell motility and matrigel invasion.
Materials and Methods
Materials and Reagents
Histone H4, anti-actin monoclonal antibodies were
purchased from Sigma (St. Louis, MO). Protein-A/G-conjugated
Sepharose beads were from Amersham/Pharmacia
(Piscataway, NJ). Monoclonal antibody 12CA5 against the
hemaagglutinin (HA) tag was obtained from Berkeley Antibody
(Berkeley, CA). Anti-PAK6 polyclonal anti-serum was custom
generated against glutathione-S-transferase-PAK6 (#292-400)
fusion peptide by Covance (Princeton, NJ). On-Target Smart
Pool of AR-specific small interference RNA (Cat#:
L-003400-00-0005) was obtained from Dharmacon (Waltham,
MA). Matrigel was purchased from BD Bioscience (Franklin
Lakes, NJ). Dihydrotestosterone (DHT) was obtained from
Steraloids Inc (Newport, RI)
Expression Vectors and Constructs
The PAK6-5A and -5E mutants were generated by replacing
wild type fragment (pcDNA3-PAK6-WT; Invitrogen, Carlsbad,
CA) directly with synthetic mutant fragments respectively (Bio-
Basic, Ontario). Expression vector pTRE (Clontech Laboratory,
Mountain View, CA) was used for cloning of tetracycline
inducible PAK6. For mammalian two-hybrid assays, the
mammalian two-hybrid expression vectors expressing full
length PAK6 and truncated mutants were constructed by
cloning the corresponding fragments in-frame with partial
herpes transactivating protein (VP16, residues 411–456) as a
fusion gene into the pACT vector (Promega, Madison, WI).
Full-length AR and truncated mutants were cloned in-frame
fused with GAL4-DBD (residues 1–147) in a pBIND vector
(Promega, Madison WI). Luciferase reporter pG5-Luc
(luciferase driven by five tandem-repeats of Gal4 binding
sequence-fused minimal promoter) (Promega) was used as the
interaction responsive reporter and a pCMV-RL (renilla
luciferase) was used as a control vector for monitoring
transfection efficiency.
Cell Culture and Transient Transfection
LNCap (CRL-1740) and PC3 (CRL-1435) cells were
purchased from ATCC (Manassas, VA). LNCap and PC3 cells
were grown in RPMI1640 (Invitrogen), supplemented with
antibiotics and 10% fetal bovine serum (FBS). LAPC4 was a
generous gift from Drs. Robert Reiter and Charles Sawyers
[12]. LAPC4 cells were grown in Iscove’s Dulbecco's modified
Eagle's medium (IMDM; high glucose Invitrogen)),
supplemented with antibiotics and 10% FBS. Cells (6 x 105)
were transfected by electroporation with a total of 10 μg of
plasmid DNA using a Gene Pulser from BioRad (Hercules,
CA).
Gel Electrophoresis and Immunoblotting
Proteins were separated by SDS-PAGE with a standard
reducing protocol. Following electrophoresis, proteins were
electrotransferred to a nitrocellulose membrane. The protein
bands were visualized by ponceau-S red staining. Blots were
destained and blocked by 5% nonfat dry milk, 0.05% Tween
20, and 1% BSA in Tris-buffered saline [10 mM Tris (pH8.0),
135 mM NaCl]. Immunoblotting was performed with designated
antibodies and visualized with an enhanced
chemiluminescence detection system (ECL, Pierce,
Supersignal, Rockford, IL) following the manufacturer's
protocol.
Immunoprecipitation
Immunoprecipitation of PAK6 was performed following a
standard protocol. In brief, cells were lysed in
immunoprecipitation RIPA buffer containing 50 mM Tris (pH
7.4), 135 mM NaCl, 1% Triton X-100 (V/V), 0.25%
deoxycholate (W/V), and 0.05% SDS (W/V) and supplemented
with protease inhibitors (2 mM PMSF, 5 mM DIFP (Diisopropyl
fluorophosphates), 5μg/ml pepstatin, 1 mM EDTA). Lysates
(1mg total protein per IP reaction) were cleared by
centrifugation at 12,000 x g for 20 min at 4°C. Supernatants
were incubated with individual antibodies (1 μg) and protein A
Sepharose beads (20 μl packed beads) at 4°C for 1 h. At the
end of incubation, beads were washed 5 times with lysis buffer.
The resulting immunoprecipitated immunocomplexes were
solubilized in 40 μl of Laemmli sample buffer, proteins were
separated using SDS-PAGE, and transferred to a nitrocellulose
membrane. The protein complex was detected by western blot
analysis and visualized on an X-ray film by exposure to ECL
(Pierce, Supersignal). For phosphopeptide mapping by mass
spectrometry, androgen-stimulated PAK6 was
immunoprecipitated from LNCap-PAK6 cell lysate using anti-
HA monoclonal antibody 12CA5 coupled to protein G
Sepharose beads. Immunoprecipitated PAK6 was isolated by
excising the corresponding PAK6 band from a SDS-PAGE gel.
Androgen-Activated PAK6 Promotes Cell Motility
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Phospho-peptides were identified by a core mass spectrometry
facility in Scripps Florida.
In vitro kinase assay
Kinase reactions of immunoprecipitated PAK6 were
performed in kinase buffer (50 mM HEPES, pH 7.4, 10 mM
MgCl2, 2 mM MnCl2 and 2 mM DTT, 200 μM ATP)
supplemented with 1.0 μg/reaction of histone H4 and 20 μCi/
reaction of radioactive ATP. These reactions were incubated
for 30 min at 30°C and stopped by addition of sample buffer
containing SDS. The samples were subjected to SDS-PAGE,
and 32P-labeled, phosphorylated proteins were visualized by
autoradiograph.
Haptotactic transwell migration and Matrigel invasion
assays
Haptotactic transwell cell migration assay was done using a
modified Boyden chamber [13]. In brief, both sides of the
transwell PET membrane were coated with fibronectin (0.5
μg/cm2 on the top side and 2.5 μg/cm2 on the bottom side).
Prostate cancer LAPC4 cells were seeded inside the well at a
density of 1 x 105 cells/ml. Cells were let to migrate for 16-24 hr
in a CO2 incubator. At the end of incubation, the transwells
were removed and the un-migrated cells at top membrane
were wiped away with a cotton swab. The migrated cells on the
bottom surface were trypsinized and quantified using CyQuant
NF (Invitrogen, Carlsbad, CA) following manufacturer’s
instructions.
The invasion assays were performed as previously described
with some modifications [14]. In brief, 12-well transwell
chambers (Costar, Cambridge, MA), 8 μm pore size, were
coated with 300 μg/cm2 growth factor reduced BD-matrigel (BD
Biosciences) by incubating at 37°C overnight. 4 x 104 LNCap
cells expressing PAK6-WT, PAK6-5A or PAK6-5E were mixed
with matrigel diluted (300 μg/ml) in RPMI1640 (supplemented
with 1% FBS) at 4°C then seeded on the matrigel coated
transwell. Cell invasion was allowed for 16-24 hr at 37°C by
adding 1.2 ml of complete media (RPMI1640/10% FBS) to the
lower chamber of the transwell. At the end of the incubation,
the non-invaded cells were scraped off using a cotton swap.
The cells migrated across the membrane to the bottom surface
of the PET membrane were stained with 1% crystal violet in
methanol. Cell number was quantified by counting cells on the
whole membrane microscopically.
Statistical analysis
All data are expressed as means ± S.E.M. To establish
significance, group mean comparisons were performed with
unpaired Student’s t-test or one-way ANOVA with post hoc
Tukey test using GraphPad Prism 5.0 (San Diego, CA, USA).
The criterion for significance was set at p ≤ 0.05.
Results
1: PAK6 activation in response to androgen stimulation
Although PAK6 is identified as an AR interacting protein, it
does not function as a co-factor in AR transcriptional activation
[1]. To investigate the relationship between AR and PAK6, we
first determined if PAK6 could be regulated via AR-mediated
androgenic signals. To test this possibility, an AR-positive,
PAK6-expressing prostate cancer LAPC4 cell line was used.
LAPC4 cells were starved in serum free media overnight
followed by stimulating with 10 nM of dihydrotestosterone
(DHT) for various times before they were harvested for kinase
assay. Androgen-stimulated PAK6 kinase activity was
determined by an anti-PAK6 antibody immunoprecipitation-
coupled in vitro kinase assay (IP-kinase assay). As shown in
Figure 1A, in response to androgen stimulation, activation of
PAK6 was evident by 1 hr and continue to be active at 3 hr
post DHT stimulation. A dose response of PAK6 activation in
response to various concentration of DHT, in a ten-fold serial
dilution (from 0.1 nM to 1,000 nM), was demonstrated by an in
vitro kinase assay (Figure 1B). However, in AR-negative PC3
cells, the PAK6 kinase activity remained unchanged in
response to androgen stimulation throughout the time course
with prolonged incubation (Figure 1C). To determine whether
AR is required for DHT-stimulated activation of PAK6, LAPC4
cells were transfected with AR specific siRNA Smart-pool
(Dharmacon) to downregulate AR expression levels. As shown
in Figure 1D (middle panel), LAPC4 cells transfected with AR-
specific siRNA (siAR) exhibited a reduced level of androgen
receptor protein expression up to 80%. The AR protein levels
remain high in cells transfected with non-silencing/sequence-
scrambled control siRNA (siScrm). These cells were subjected
to the same androgen stimulation coupled with a IP-kinase
assay as described above. Shown in Figure 1C (upper panel),
as a result of AR knock-down in LAPC4 cells, androgen
treatment failed to activate PAK6 kinase activity as it did in
non-knocking down control siRNA. The expression levels of AR
and PAK6 in LNCap, LAPC4 and PC3 cell are shown in Figure
1E. Together, these results indicate that PAK6 activation in
response to DHT stimulation is an AR-dependent event.
2: Mapping the PAK6 AR-interacting domain
Since PAK6 is identified as an androgen-dependent AR-
interacting protein, we want to determine if the interaction per
se is required for androgen simulated PAK6 activation. We
mapped the domain/structural requirement of PAK6
responsible for interacting with AR using a mammalian two-
hybrid assay. The mammalian two-hybrid assays were
performed by co-transfecting the following expression vectors:
a VP-16 transactivation domain fused with various deletion
mutants of PAK6 (see Figure 2A for details), and a GAL4 DNA-
binding domain fused with AR, and a pGal4-Luc reporter gene.
The interactions were determined by an increased activity in a
luciferase reporter assay. The results from the mammalian two-
hybrid assay are shown in Figure 2A lower panel. Based on
these results, an AR interacting domain of PAK6 is identified
between residues #292-368 that localizes at the immediate
upstream of the catalytic domain (Figure 2A). Coincidentally,
the current identified AR-interacting domain overlaps with the
PAK6 fragment originally identified through the yeast two-
hybrid screening that spanning between residues #285-618
[1,2]. Reciprocally, the region of AR responsible for interacting
with PAK6 was also identified by the same two-hybrid assay.
Androgen-Activated PAK6 Promotes Cell Motility
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As shown in Figure 2B, a positive interaction between PAK6
and AR DBD-hinge-LBD (DNA-binding, hinge and ligand-
binding domain) (residues #501-918) was detected by this
assay while DBD-hinge (residues #501-660) or LBD (residues
#660-918) alone only exhibit partial interactive activities.
3: Identification of Phospho-Amino Acid Residues in
Androgen Stimulation-Activated PAK6
Next, we set out to identify the relevant amino acid residues
of PAK6 within the AR-binding domain that actively participate
in the regulation of PAK6 and AR interaction. We examined the
sequence composition of the AR-binding domain of PAK6 to
Figure 1.  Androgen-stimulated PAK6 activation is mediated by androgen receptor. LAPC4 cells were plated overnight in
IMDM supplemented with 10% charcoal-stripped fetal bovine serum.  (A) Time course (0 h: non-treated) study of PAK6
activation in response to 10 nM dihydrotestosterone (DHT) stimulation in LAPC4 cells. (B) A DHT ten-fold serial dilution (0 nM: non-
treated; and DHT-treated 0.1 nM to 1,000 nM) dose response of PAK6 activation. (C) 10 nM DHT does not activate PAK6 kinase
activity in androgen receptor negative PC3-PAK6 cell. (D) PAK6 in vitro kinase assay demonstrates knocking down of AR by siRNA
diminishes androgen-stimulated PAK6 activation in LAPC4 cells. Middle panels depict the expression levels of AR and PAK6 in
LNCap-PAK6 cells in response to AR specific siRNA. (E) Whole lysate of LNCap, LAPC4 and PC3 blot against anti-PAK6,anti-AR
and anti-actin.
doi: 10.1371/journal.pone.0077367.g001
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Figure 2.  Mapping PAK6-AR interacting domain by mammalian two-hybrid assay.  (A) Schematic depiction of full-length PAK6
and boundaries of truncated PAK6mutants encompassing various domains in the left panel. The right panel shows the results of
mammalian two-hybrid assays. The interaction was determined by measuring the luciferase activities of HEK 293 cells transiently
transfected with PAK6 full-length and deletion mutants fused in-frame downstream of VP16 transactivation domain in a pACT vector
and GAL4 DBD fused AR in a pBIND vector. Data represent the mean ± SEM (n = 3). *p<0.05, compared to full-length PAK6, one-
way ANOVA. (B) The left panel shows the schematic depiction of full-length AR and boundaries of AR truncated mutants
encompassing various domains. A mammalian two-hybrid assay was performed by co-transfecting HEK-293cells with pACT-AR or
truncated AR mutants, as indicated, with pBIND-PAK6 and pG5-Luc reporter construct. In both sets of experiment, a renilla
luciferase reporter activity was used as a transfection internal control. The luciferase activity was normalized against the internal
control and the vector basal control groups. Data represent the mean ± SEM (n = 3). *p<0.05, compared to full-length AR, one-way
ANOVA.
doi: 10.1371/journal.pone.0077367.g002
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look for potential residues that may take part in the regulation
of this interaction. We determined the possible phosphorylation
site in immunoprecipitated androgen-activated PAK6 by mass
spectrometry. As depicted in Figure 3, mass spectrometry
analysis revealed multiple phospho-amino acids in PAK6
(Table 1 and the Fig S1-S6 in File S1) including one N-terminal
peptide containing phospho-serine-113, one peptide containing
phospho-serine-560 in the kinase domain and stretches of
multiple phosphopeptides that localized within the ‘AR-binding
domain’ of PAK6, including phospho-serines of residues: #308,
#346 and #360; and phospho-threonine of residues: #326 and
#354 (Figure 3, Table 1 and Figure S1-S6 in File S1).
Table 1. PAK6 phospho-peptide sequences identified by
mass spectrometry.








4: Androgen-stimulated PAK6 activation requires direct
interaction between AR and PAK6
To test the potential involvement of AR-binding-domain
phosphorylation in PAK6-AR interaction, we generated two
PAK6 mutants that have those phosphorylation sites modified
by either substituting the serine (at residues #308, 346 and
360) and threonine (residue #326 and 354) residues to alanine
(S or T→A; PAK6-5A) to mimic "non-phosphorylated" state or
to glutamic acid (S or T→E; PAK6-5E) to mimic "constitutive
phosphorylated" state (Figure 3 and 4). The effects of these
phosphorylation mimicking mutations on the interaction
between PAK6 and AR were assessed by a mammalian two-
hybrid assay. As shown in Figure 4A, the interaction between
AR and PAK6-5A remained high as compared to PAK6-WT. In
contrast, mutagenesis by substituting serines/threonine with
glutamic acid, namely the phospho-mimetic PAK6-5E mutant,
exhibited diminished androgen-dependent interaction between
AR and PAK6 (Figure 4A). These interactions were further
demonstrated through a reciprocal co-immunoprecipitation
assay by co-transfection of AR and PAK6-WT, -5A or 5E. As
shown in Figure 4B, an androgen-dependent interaction
between AR and PAK6 is evident in PAK6-WT and PAK6-5A
groups but no association was detected between AR and PAK6
phospho-mimicking mutant PAK6-5E. A minor weak interaction
between AR and PAK6-5A was detectable in the anti-PAK6
immunoprecipitates even in the absence of androgen (Figure
4B, third panel lane 4). These results indicate that the
interaction between PAK6 and AR is modulated by multi-
phosphorylation of the PAK6 AR-binding-domain.
Figure 3.  Schematic diagram of PAK6 AR-binding domain phosphorylation site mutations.  The AR-binding domain
constitutive non-phosphorylation mutant PAK6-5A is generated by substituting three serine and two threonine residues with alanine
(A). The AR-binding domain constitutive phosphorylation mimic mutant PAK6-5E is generated by substituting Serine/Threonine
residues with glutamic acid (E).
doi: 10.1371/journal.pone.0077367.g003
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Next, we determined if the interaction between AR and PAK6
is necessary for androgen-stimulated PAK6 activation. To this
end, LNCap cells stably expressing PAK6-WT, PAK6-5A or
PAK6-5E were established. The effects of these mutations on
Figure 4.  Phosphorylation site mutants of PAK6-5A and PAK6-5E exhibit altered ability to interact with AR and androgen-
stimulated kinase activation.  (A) Interactions between AR and PAK6-5A, PAK6-5E are assessed by a mammalian two-hybrid
assay. Full-length AR is cloned in-frame downstream of VP16 transactivation domain with a HA-tag using a pACT vector. PAK6-wt,
-5A and 5E were cloned in-frame downstream of GAL4 DBD with a HA tag using a pBIND vector. A mammalian two-hybrid assay
was performed by co-transfecting HEK-293cells with pACT-AR or AR truncated mutants, as indicated, with pBIND-PAK6 and pG5-
Luc vector. Cells were treated with vehicle control or DHT (10 nM) for 20 h followed by dual luciferase assay. A renilla luciferase
reporter activity was used as a transfection internal control. The luciferase activity was normalized by the internal control and the
vector basal control groups. Data represent the mean ± SEM (n=3, *p<0.01 compared to their respective vehicle controls; Student’s
t-test). (B) A reciprocal immunoprecipitation assay was performed using AR and PAK6-WT, -5A and -5E mutants. HEK-293 cells
were transfected with equal amount of AR and PAK6 expression vectors in the presence or absence of 10 nM DHT. Twenty hours
post-transfection either AR or PAK6 was immunoprecipitated using antibodies specifically for either molecule then reciprocally
probed by western blot for presence of co-precipitated interacting proteins as depicted. (C) A representative experiment of
androgen-stimulated activation of PAK6-WT, PAK6-5A and PAK6-5E in an in vitro kinase assay. The upper phosphorylation band is
PAK6 autophosphorylation. The lower bands are the phosphorylation of the exogenous substrate histone H4. (D) Quantification of
relative kinase activities of in vitro kinase assays from (C). Data represent the mean ± SEM (n=4, *p<0.01 compared to their
respective vehicle controls; Student’s t-test).
doi: 10.1371/journal.pone.0077367.g004
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androgen-stimulated activation of PAK6 were determined by an
immunoprecipitaion-coupled in vitro kinase assay. Figure 4C is
shown as a representative experiment of the IP-kinase assay.
The quantification of multiple experiments (n=5) of androgen-
stimulated activation of PAK6-WT, -5A and -5E is shown in
Figure 4D where PAK6-5A remained responsive to androgen
stimulation-induced activation as its WT counterpart (p<0.01).
On the other hand, there is a clear elevation of the baseline
kinase activity of in the non-treated PAK6-5E group (Figure 4C
and 4D) suggesting PAK6-5E mutant may be in the status of
partial activation. The androgen stimulation has no effects on
further promoting PAK6-5E mutant autophosphorylation or
kinase activity toward the exogenous histone H4 substrate. The
absence of androgen-stimulated kinase response of LNCap-
PAK6-5E cells can potentially be attributed to the lack of
interaction between AR and PAK6-5E. Taken together, our
results support the notion that a physical interaction between
AR and PAK6 is required in androgen-stimulated PAK6
activation.
5: Activated PAK6 promotes prostate cancer cell
motility
To characterize the physiological consequences of
androgen-stimulated PAK6 activation, we established LNCap
cell lines (LNCap-tetON-PAK6) ectopically expressing PAK6
WT under the control of a tetracycline-inducible promoter. The
inducible PAK6 LNCap cell lines allowed us to evaluate the
event of androgen stimulation and PAK6 activation in a
homogeneous clonal cell background. As shown in Figure 5A,
tetracycline-dependent inductions of PAK6 expression are
demonstrated in two representative LNCap-tetON-PAK6 clones
while expression of AR is not affected by the treatment. In an in
vitro kinase assay, the tetracycline-induced PAK6 responds to
androgen stimulation with increased kinase activity towards
exogenous substrate histone H4 (Figure 5B, lower bands) and
an elevated autophosphorylation (Figure 5B, upper bands).
Although no PAK6 expression was detected in the western blot
of non-induced groups (Figure 5A lanes 1 and 3 upper panel),
minor PAK6 autophosphrylation bands are visible (Figure 5B,
lanes 1 and 3 upper bands) suggested a low level leakiness of
the tetracycline inducible promoter.
To illustrate the effects of androgen-stimulated PAK6
activation in regulating cell motility, a transwell haptotatic
migration assay using a modified Boyden chamber was
performed as described previously [15]. As shown in Figure
5C, the non-induced LNCap-tetON-PAK6 cells exhibit baseline
motility in the absence of androgen while the tetracycline-
induced androgen-stimulated LN-tetON-PAK6 cells exhibit
highest migratory motility (p<0.001). A moderate increase of
cell migration is also observed in the presence of androgen
without tetracycline induction (p<0.01) that may result from the
expression of a low level PAK6 due to promoter leakiness. No
promotion of migration can be observed in cells induced to
express PAK6 without androgen stimulation.
A matrigel invasion assay was performed to determine the
potential effects of PAK6 activation on modulating the invasive
ability of LNCap. As shown in Figure 5D, androgen stimulation
dramatically promotes matrigel invasion (p<0.001) of
tetracycline-induced LNCap-tetON-PAK6 cells as compared to
non-induced cells. A less prominent effect of androgen-
stimulation promoted invasion is also evident in non-induced
LNCap cells presumably due to a leaky PAK6 expression.
These results indicate androgen-stimulated PAK6 activation
promotes LNCap cells haptotactic migration and matrigel
invasion.
To further examine the role of AR-PAK6 interaction played in
promoting the androgen-stimulated cell motility and invasion,
we established LNCap cell lines stably expressing PAK6 WT,
-5A or -5E. The same haptotatic assay and matrigel invasion
assay were employed for this purpose. As shown in Figure 6A,
androgen stimulation promoted-cell migration was observed in
LNCap cells expressing either PAK-WT or PAK6-5A (p<0.001).
Consistent with an elevated baseline kinase activity of
PAK6-5E as observed in previous section (Figure 4C and 4D),
a higher baseline motility was also observed in LNCap-5E cells
in the absence of androgen stimulation. Consequently, the
LNCap cells expressing PAK6-5E did not respond to androgen
stimulation with further increase of cell motility
A matrigel invasion assay was performed to determine the
potential effects of PAK6 activation on modulating the invasive
ability of LNCap expressing various mutants of PAK6. As
shown in Figure 6B, androgen stimulation dramatically
promotes matrigel invasion in LNCap-PAK6-WT and LNCap-
PAK6-5A cells (p<0.001). Representative micrographs of the
invaded cells from each group are shown in Figure 6C. Similar
to the observation described above, with an already elevated
baseline invasion, the LNCap-5E exhibited no further
upregulation of androgen-stimulated invasion. These
observations are consistent with the notion that a direct
interaction between AR and PAK6 is required for the kinase
activation, thereafter, promotion of cell motility and invasion.
Discussion
In current study, we present evidence linking androgen and
PAK6 activation to prostate cancer cell motility and invasion.
We demonstrated that androgen stimulation acts as an
extracellular signal that activates PAK6 in an androgen
receptor-dependent manner in prostate cancer LAPC4 and
LNCap cells. The androgen-stimulated activation of PAK6 is
accompanied by multiple serine/threonine phosphorylation as
determined by mass spectrometry. We showed that the
interaction between PAK6 and AR is regulated by the PAK6’s
AR-binding domain phosphorylation. Our data indicate that a
direct interaction between AR and PAK6 is necessary for the
activation of PAK6 in response to androgen stimulation.
Consequently, androgen-stimulated PAK6 activation promotes
prostate cancer cell motility and invasion.
Our finding of androgen as an extracellular stimulus for
PAK6 activation represents a novel androgen-dependent AR
non-genomic signal pathway. AR can form a ternary
membrane-associated signal complex with c-Src, estrogen
receptor, and function cooperatively to activate Src kinase
activity [16-18] to stimulate prostate cancer cell growth in a
non-transcription-dependent manner. AR is also demonstrated
to signal from plasma membrane lipid raft, a cholesterol rich
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sub-domain, to activate Akt or Erk [19-21] that promote cell
growth and survival. Our data indicate that androgen-
stimulated PAK6 activation requires a direct interaction
between PAK6 and AR. While the exact mechanism of this
activation process remains to be further characterized, two
recent reports [4,5] describe the identification of a N-terminal
localized pseudosubstrate-like autoinhibitory domain in group 2
PAKs may offer insights to a potential mechanism of our
observations. In those reports, an intra-molecular interaction
between the auto-inhibitory domain and the catalytic domain
was determined to be responsible for keeping the group 2PAKs
inactive, whilst interruption of this interaction activates it. The
AR-stimulated phosphorylation of PAK6’s AR-binding domain,
as described in the current study, may result in a
conformational change that consequently activates PAK6 by
perturbing the interaction between auto-inhibitory domain and
catalytic domain. This possibility is further echoed by our result
that the ‘phosphorylation-mimicking’ mutant PAK6-5E exhibits
Figure 5.  Androgen-stimulated PAK6 activation promotes cell motility and invasion in LNCap cells stably transfected with
tetracycline-inducible PAK6 vector (LNCap-tetON-PAK6).  (A) Anti-PAK6 immuno-blot of tetracycline inducible PAK6 expression
in two different clones of LNCap cells depicts the induction of PAK6 expression by doxycycline (1 μg/ml). (B) In vitro kinase activities
of doxycycline-induced PAK6 kinase from individual clones using histone H4 as an exogenous substrate. (C) Androgen stimulation
promotes transwell cell migration of doxycycline-induced LNCap-tetOn-PAK6 cells. Data represent the mean ± SEM. (n=6).
**p<0.01, ***p<0.001 compared to their respective –DHT control; Student’s t-test. (D) Androgen stimulation promotes matrigel
invasion of doxycycline-induced LNCap-tetON-PAK6 cells. All experiments were repeated at least three times, with consistent
results. Data represent the mean ± SEM. (n=6). ***p<0.001 compared to their respective –DHT control; Student’s t-test .
doi: 10.1371/journal.pone.0077367.g005
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Figure 6.  Androgen-stimulated PAK6 activation promotes cell motility and invasion in LNCap cells stably expressing
PAK6-WT, PAK6-5A and PAK6-5E.  (A) Androgen stimulation promotes transwell cell migration of LNCap-PAK6-WT and LNCap-
PAK6-5A cells. LNCap-PAK6-5E cells, albeit with elevated baseline motility, do not respond to androgen stimulation with increased
migration. Data represent the mean ± SEM (n=3). **p<0.01, ***p<0.001 compared to their respective –DHT controls; Student’s t-
test. (B) Androgen stimulation promotes matrigel invasion of LNCap PAK6-WT and LNCap-PAK6-5 cells. Similarly, LNCap-
PAK6-5E cells, albeit with elevated baseline invasion, do not respond to androgen stimulation with increased invasion. Data
represent the mean ± SEM (n=3). *p<0.05, **p<0.01 compared to their respective –DHT controls; Student’s t-test. (C)
Representative micrographs of invaded LNCap and PAK6-derivertives cells depicted in (B). Scale bar: 50 μm.
doi: 10.1371/journal.pone.0077367.g006
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higher basal kinase activity in an in vitro kinase assay (Figure
4C and 4D).
The AR-binding domain (residues 292-368) identified in
current study is included in and as part of the original yeast
two-hybrid screening identified AR-interacting PAK6 fragment
(residues 285-681) [1]. An FxxMF motif located between
residues #261-265 of PAK6 was recently described to bind AR
[22]. Notably, the FxxMF motif is not part of the original PAK6
fragment identified by the yeast two-hybrid screening [22]. This
suggests that the FxxMF motif may cooperative with additional
structural components of PAK6 to mediate the interaction
between PAK6 and AR. It is conceivable that additional
‘regulatory domain(s)’ exists in PAK6 that also partakes in the
interaction between AR and PAK6. As shown in Figure 2A, the
interaction between AR and PAK6 Δ190 deletion mutant
appears to be stronger than the interaction between AR and
full-length PAK6 in the mammalian two hybrid assay. This
suggests a potential inhibitory domain, such as the ‘auto-
inhibitory domain’ described above, may be present in amino
acids #1-#190 of PAK6 that participates in the regulation of the
PAK6-AR interaction. Moreover, our data demonstrate that
phosphorylation of AR-binding domain profoundly influences
the interaction between PAK6 and AR. Although the identity of
the kinase(s) responsible for this phosphorylation is yet to be
determined, our results underscore the potential complexity of
the multistep nature of androgen-stimulated PAK6 activation.
As evident from mammalian two-hybrid assay results depicted
in Figures 2 and 4A, it is plausible that the PAK6-binding
domain of AR only becomes accessible to interact with PAK6
upon androgen ligation. Once bound with AR, PAK6 may
undergo autophosphorylation or be phosphorylated by an
additional kinase(s) yet to be identified. Phosphorylation of AR-
binding domain disengages PAK6 from its AR association that
eventually results in full kinase activation. As for mapping of
AR, the PAK6-binding domain of AR was previously
determined to localize at the AR ligand-binding domain (LBD)
excluding the AR DNA-binding domain (DBD) by an GST pull-
down assay in vitro [2]. In the current mammalian two-hybrid
assay, we show that both DBD and LBD of AR are required for
a strong interaction between these two molecules in vivo since
DBD or LBD alone exhibits only moderate PAK6-interacting
activities. Nonetheless, these two seemingly different
observations are not mutually exclusive; rather it highlights the
limitations of different techniques used to determine the
interactions.
In conclusion, the finding that androgen stimulation promotes
cell motility and invasion via activation of PAK6 is significant.
This suggests a potential role of PAK6 in prostate cancer
metastatic progression. It also offers a plausible mechanism for
the previously reported [23] positive correlations between
PAK6 expression and high-grade prostate cancer Since steroid
hormone such as androgen has long been recognized in
promoting prostate cancer progression, our results provide a
direct molecular link between androgenic signal and metastasis
related molecular events.
Supporting Information
File S1.  Supporting Figures S1-S6.
Figure S1. Identification of Serine-308 as a site of
phosphorylation. The amino acid sequence is provided above
the spectrum, and the masses above and below the sequence
correspond to the theoretical b- and y-type product ions,
respectively. The masses provided are the singly-protonated,
monoisotopic product ion masses. The observed singly-
protonated product ions are underlined. For simplicity, all
doubly protonated ions are not labeled in the spectra as they
exist at 50% abundance or less. Asterisks indicate ions that
result from neutral loss of H3PO4.
Figure S2. Identification of Threonine-326 as a site of
phosphorylation. The amino acid sequence is provided above
the spectrum, and the masses above and below the sequence
correspond to the theoretical b- and y-type product ions,
respectively. The masses provided are the singly-protonated,
monoisotopic product ion masses. The observed singly-
protonated product ions are underlined. Asterisks indicate ions
that result from neutral loss of H3PO4 from fragment ions.
Additionally, the presence of the second site of phosphorylation
is determined due to accurate mass of the peptide, however,
the first fragment ion representing this site is located at y7, thus
the phosphorylation could exist in any of the sites shown in
brackets.
Figure S3. Identification of Serine-346 as a site of
phosphorylation. The amino acid sequence is provided above
the spectrum, and the masses above and below the sequence
correspond to the theoretical b- and y-type product ions,
respectively. The masses provided are the singly-protonated,
monoisotopic product ion masses. The observed singly-
protonated product ions are underlined. The site of
phosphorylation cannot be definetively identified, due to lack of
specific ions related to either site of phosphorylation, however
we hypothesize that the phosphorylation is on the first of the
serine residues due to lack of tryptic cleavage at the preceding
site. Asterisks indicate ions that result from neutral loss of
H3PO4.
Figure S4. Identification of Thrionine-354 and Serine-360 as
sites of phosphorylation. The amino acid sequence is provided
above the spectrum, and the masses above and below the
sequence correspond to the theoretical b- and y-type product
ions, respectively. The masses provided are the singly-
protonated, monoisotopic product ion masses. The observed
singly-protonated product ions are underlined. Asterisks
indicate ions that result from neutral loss of H3PO4 from
fragment ions. This doubly phosphorylated peptide loses two
phosphoric acid groups from the parent ion which are marked
with *.
Figure S5. Identification of Serine-360 as a site of
phosphorylation. The amino acid sequence is provided above
the spectrum, and the masses above and below the sequence
correspond to the theoretical b- and y-type product ions,
respectively. The masses provided are the singly-protonated,
monoisotopic product ion masses. The observed singly-
protonated product ions are underlined. Asterisks indicate ions
that result from neutral loss of H3PO4 from fragment ions.
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Figure S6. Identification of Serine560 as a site of
phosphorylation. The amino acid sequence is provided above
the spectrum, and the masses above and below the sequence
correspond to the theoretical b- and y-type product ions,
respectively. The masses provided are the singly-protonated,
monoisotopic product ion masses. The observed singly-
protonated product ions are underlined. Asterisks indicate ions
that result from neutral loss of H3PO4.
(PDF)
Acknowledgements
The authors thank the editorial assistance by Ms. Sylvia Lin.
Author Contributions
Conceived and designed the experiments: MLL JW XY.
Performed the experiments: XL CJ JB. Analyzed the data: MLL
JW XY. Contributed reagents/materials/analysis tools: MLL JW.
Wrote the manuscript: MLL JW. Proteomic phosphopeptide
mapping: JB.
References
1. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD et al. (2002) AR
and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol
16: 85-99. doi:10.1210/me.16.1.85. PubMed: 11773441.
2. Yang F, Li X, Sharma M, Zarnegar M, Lim B et al. (2001) Androgen
receptor specifically interacts with a novel p21-activated kinase, PAK6.
J Biol Chem 276: 15345-15353. doi:10.1074/jbc.M010311200.
PubMed: 11278661.
3. Jaffer ZM, Chernoff J (2002) p21-activated kinases: three more join the
Pak. Int J Biochem Cell Biol 34: 713-717. doi:10.1016/
S1357-2725(01)00158-3. PubMed: 11950587.
4. Ha BH, Davis MJ, Chen C, Lou HJ, Gao J et al. (2012) Type. p. II p21-
activated kinases (PAKs) are regulated by an autoinhibitory
pseudosubstrate. Proc Natl Acad Sci U S A 109: 16107-16112
5. Baskaran Y, Ng YW, Selamat W, Ling FT, Manser E (2012) Group I
and II mammalian PAKs have different modes of activation by Cdc42.
EMBO Rep 13: 653-659. doi:10.1038/embor.2012.75. PubMed:
22653441.
6. Ahmed T, Shea K, Masters JR, Jones GE, Wells CM (2008) A PAK4-
LIMK1 pathway drives prostate cancer cell migration downstream of
HGF. Cell Signal 20: 1320-1328. doi:10.1016/j.cellsig.2008.02.021.
PubMed: 18424072.
7. Wells CM, Abo A, Ridley AJ (2002) PAK4 is activated via PI3K in HGF-
stimulated epithelial cells. J Cell Sci 115: 3947-3956. doi:10.1242/jcs.
00080. PubMed: 12244132.
8. Cotteret S, Jaffer ZM, Beeser A, Chernoff J (2003) p21-Activated
kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by
phosphorylating BAD. Mol Cell Biol 23: 5526-5539. doi:10.1128/MCB.
23.16.5526-5539.2003. PubMed: 12897128.
9. Schürmann A, Mooney AF, Sanders LC, Sells MA, Wang HG et al.
(2000) p21-activated kinase 1 phosphorylates the death agonist bad
and protects cells from apoptosis. Mol Cell Biol 20: 453-461. doi:
10.1128/MCB.20.2.453-461.2000. PubMed: 10611223.
10. Jin S, Zhuo Y, Guo W, Field J (2005) p21-activated Kinase 1 (Pak1)-
dependent phosphorylation of Raf-1 regulates its mitochondrial
localization, phosphorylation of BAD, and Bcl-2 association. J Biol
Chem 280: 24698-24705. doi:10.1074/jbc.M413374200. PubMed:
15849194.
11. Arias-Romero LE, Chernoff J (2008) A tale of two Paks. Biol Cell 100:
97-108. doi:10.1042/BC20070109. PubMed: 18199048.
12. Abrham G, Volpe M, Shpungin S, Nir U (2009) TMF/ARA160
downregulates proangiogenic genes and attenuates the progression of
PC3 xenografts. Int J Cancer 125: 43-53. doi:10.1002/ijc.24277.
PubMed: 19330832.
13. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE (2008) Androgen
receptor and invasion in prostate cancer. Cancer Res 68: 1128-1135.
doi:10.1158/0008-5472.CAN-07-1929. PubMed: 18281488.
14. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF et al. (2008) SOX9 is
expressed in human fetal prostate epithelium and enhances prostate
cancer invasion. Cancer Res 68: 1625-1630. doi:
10.1158/0008-5472.CAN-07-5915. PubMed: 18339840.
15. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX et al. (2003)
Androgen stimulates matrix metalloproteinase-2 expression in human
prostate cancer. Endocrinology 144: 1656-1663. doi:10.1210/en.
2002-0157. PubMed: 12697668.
16. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A et al.
(2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src
complex triggers prostate cancer cell proliferation. EMBO J 19:
5406-5417. doi:10.1093/emboj/19.20.5406. PubMed: 11032808.
17. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in
human cancer. Cancer Cell 6: 209-214. doi:10.1016/j.ccr.2004.09.001.
PubMed: 15380511.
18. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL et al. (2001)
Nongenotropic, sex-nonspecific signaling through the estrogen or
androgen receptors: dissociation from transcriptional activity. Cell 104:
719-730. doi:10.1016/S0092-8674(02)08100-X. PubMed: 11257226.
19. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR (2007)
Phosphoinositide 3-kinase-independent non-genomic signals transit
from the androgen receptor to Akt1 in membrane raft microdomains. J
Biol Chem 282: 29584-29593. doi:10.1074/jbc.M703310200. PubMed:
17635910.
20. Gatson JW, Kaur P, Singh M (2006) Dihydrotestosterone differentially
modulates the mitogen-activated protein kinase and the
phosphoinositide 3-kinase/Akt pathways through the nuclear and novel
membrane androgen receptor in C6 cells. Endocrinology 147:
2028-2034. PubMed: 16410299.
21. Gatson JW, Singh M (2007) Activation of a membrane-associated
androgen receptor promotes cell death in primary cortical astrocytes.
Endocrinology 148: 2458-2464. doi:10.1210/en.2006-1443. PubMed:
17303658.
22. van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC,
Houtsmuller AB et al. (2006) Novel FXXFF and FXXMF motifs in
androgen receptor cofactors mediate high affinity and specific
interactions with the ligand-binding domain. J Biol Chem 281:
19407-19416. doi:10.1074/jbc.M602567200. PubMed: 16690616.
23. Kaur R, Yuan X, Lu ML, Balk SP (2008) Increased PAK6 expression in
prostate cancer and identification of PAK6 associated proteins.
Prostate 68: 1510-1516. doi:10.1002/pros.20787. PubMed: 18642328.
Androgen-Activated PAK6 Promotes Cell Motility
PLOS ONE | www.plosone.org 12 October 2013 | Volume 8 | Issue 10 | e77367
